Softwr

Healthcare · head to head

Paige vs RXNT

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite
RXNT logo

RXNT

Healthcare

Cloud practice management and EHR software with a la carte modules

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; RXNT specific pricing tiers not displayed; plans reference starting at $118/month
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and RXNT actually diverge.

Attributes where Paige and RXNT differ
AttributePaigeRXNT
Pricing modelquotesubscription
PlatformsWeb, Cloud, On-premiseWeb

Identical on both: starting price (On request), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in RXNT

Nothing recorded that Paige does not also cover.

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot RXNT
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot RXNT
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot RXNT
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot RXNT

RXNT

  • Running entire medical practices from single integrated platformnot Paige
  • Managing electronic prescriptions including controlled Schedule II-V drugsnot Paige
  • Streamlining billing and claims management with unlimited claim processingnot Paige
  • Supporting specialty workflows for mental health and hospice providersnot Paige
  • Capturing appointment reminders and patient billing through patient portalnot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

RXNT

  • Specific pricing tiers not displayed; plans reference starting at $118/month
  • E-prescribing only available with yearly subscription
  • Requires contacting sales for personalized pricing

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

RXNT

On request

No published plan breakdown. See the RXNT review.

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Choose RXNT if

Nothing in the data separates RXNT from Paige on the points above - pick on price and on how each one feels to use.

RXNT review

Questions people ask

Is Paige or RXNT better?
Neither clearly leads. Paige starts at On request and RXNT at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or RXNT?
Paige starts at On request and RXNT at On request.
Does Paige or RXNT run on more platforms?
Paige runs on Web, Cloud, On-premise. RXNT runs on Web.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what RXNT is typically brought in for.
What can Paige do that RXNT cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

RXNT: What is RXNT's pricing model?

RXNT offers a-la-carte and bundled subscription options with monthly or annual billing. Annual subscriptions receive a 10% discount. Pricing starts at $118/month, though specific tier pricing is not displayed.

Source
Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

RXNT: What are the additional costs for RXNT?

RXNT charges $85 per year for EPCS (Electronic Prescribing of Controlled Substances) including ID proofing and biometric authentication. Non-prescribing staff also have license fees, and data imports and extended onboarding are available at additional cost.

Source
Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

RXNT: What onboarding support does RXNT provide?

RXNT includes 45 days of onboarding with the EHR Bundle and 60 days with the Practice Management and Full Suite bundles.

Source
Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Paige

More on RXNT

Keep looking

Other head to heads